Aclarion, Inc. has announced a direct offering of 3,380,276 shares of common stock at $0.142 per share, raising gross proceeds of approximately $480,000. The offering is expected to close on or about January 6, 2025.The company intends to use the net proceeds to fund market development, clinical evidence, product development, quality initiatives, and general administrative support. Dawson James Securities, Inc. is acting as the exclusive placement agent for the offering.Aclarion is currently not in compliance with Nasdaq's minimum bid price and stockholders' equity requirements. The company has until April 7, 2025 to regain compliance with the bid price requirement and until January 31, 2025 for the stockholders' equity requirement. Aclarion is evaluating options to regain compliance and maintain its Nasdaq listing.

Aclarion, Inc. has announced a direct offering of 3,380,276 shares of common stock at $0.142 per share, raising gross proceeds of approximately $480,000. The offering is expected to close on or about January 6, 2025.The company intends to use the net proceeds to fund market development, clinical evidence, product development, quality initiatives, and general administrative support. Dawson James Securities, Inc. is acting as the exclusive placement agent for the offering.Aclarion is currently not in compliance with Nasdaq's minimum bid price and stockholders' equity requirements. The company has until April 7, 2025 to regain compliance with the bid price requirement and until January 31, 2025 for the stockholders' equity requirement. Aclarion is evaluating options to regain compliance and maintain its Nasdaq listing.